Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation

Fernández-Ros, Nerea; Iñarrairaegui, Mercedes; Paramo, J.A.; Berasain, Carmen; Avila, Matı́as A.; Chopitea, Á.; Varo, Nerea; Sarobe, Pablo; Bilbao, J.I.; Domínguez, I.; D’Avola, Delia; Herrero, J.I.; Quiroga, Jorge; Sangro, Bruno

doi:10.1111/liv.12592

Cited by 61 publications

(42 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Apart from gastric cancer patients, the initial d-dimer levels of other dead patients were higher than 1.00 mg/L, including patients in liver cancer, pancreatic cancer, lung cancer and gynaecologic cancer. These results consist with other reports before [24, 25, 26, 27, and 28]. The previous study with regard to lung cancer found the d-dimer median concentration was 0.84mg/L [29].…”

Section: Discussionsupporting

confidence: 92%

Tumor-Specific D-Dimer Concentration Ranges and Influencing Factors: A Cross-Sectional Study

Lei

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

D-dimer level in cancer patients is associated with risk of venous thromboembolism and deep venous thrombosis. Most cancer patients have “abnormal” D-dimer levels based on the current normal reference range. To investigate tumor-specific D-dimer reference range, we compared D-dimer levels for nine different tumour types with healthy controls by using simultaneous quantile regression and constructing a median, 5th percentile, and 95th percentile model of normal tumour D-dimer concentration. Associations with tumour primary site, stage, pathological type, and treatment were also explored. Additionally, 190 patients were tracked to reveal the relevance of initial D-dimer levels to cancer prognosis. D-dimer ranges (median, 5th, 95th) in various cancers (mg/L) were: liver 1.12, 0.27, 5.25; pancreatic 0.96, 0.23, 4.81; breast 0.44, 0.2, 2.17; gastric 0.65, 0.22, 5.03; colorectal 0.73, 0.22, 4.45; lung 0.7, 0.25, 4.0; gynaecological 0.61, 0.22, 3.98; oesophageal 0.23, 0.7, 3.45; and head and neck 0.22, 0.44, 2.19. All were significantly higher than that of healthy controls (0.18, 0.07, 0.57). D-dimer peaked 1–2 days postoperatively but had decreased to the normal range by 1 week. Additionally, cancer patients with high initial D-dimer were shown a tendency of poor prognosis in survival rate. In conclusion, D-dimer levels in cancer depend on patient age, tumour primary site, and tumour stage. Thrombosis prevention is necessary if D-dimer has not decreased to the tumor-specific baseline a week after surgery.

show abstract

Section: Discussionsupporting

confidence: 92%

Tumor-Specific D-Dimer Concentration Ranges and Influencing Factors: A Cross-Sectional Study

Lei

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…In an early stage after radioembolization, serum markers show an induction of oxidative stress. Simultaneously, proinflammatory pathways are activated, resulting in endothelial injury with the activation of the coagulation cascade (57). Jaundice and ascites, in the absence of tumor progression or bile duct dilatation, are the main symptoms of radioembolization-induced liver disease (56,58).…”

Section: Clinical Outcome and Tumor Responsementioning

confidence: 99%

⁹⁰Y Hepatic Radioembolization: An Update on Current Practice and Recent Developments

et al. 2015

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to (1) describe the status of the current literature regarding new indications for radioembolization; (2) describe standard hepatic vascularization, identify common routes for extrahepatic depositions, and judge when "skeletization" of hepatic arteries could be unnecessary; and (3) appraise the different methods of activity calculation and recognize the strengths and pitfalls of pretreatment and posttreatment dosimetry.Financial Disclosure: Dr. Lam is a consultant/advisor for BTG International and a meeting participant/lecturer for SirTex Medical. The authors of this article have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) through July 2018.Radioembolization is an established treatment modality that has been subjected to many improvements over the last decade. Developments are occurring at a high pace, affecting patient selection and treatment. The aim of this review is therefore to provide an overview of current practice, with a focus on recent developments in the field of radioembolization. Several practical issues and recommendations in the application of radioembolization will be discussed, ranging from patient selection to treatment response and future applications.

show abstract

“…Riaz et al [40] and Atassi et al [41] provided comprehensive reviews of side effects and multimodal imaging, respectively, after radioembolization. Radiation-induced cholecystitis is a rare event occurring in about 0.8% of patients, and radioembolization of HCC activates liver regeneration, produces oxidative stress, and activates the inflammatory cytokines and the coagulation cascade [42, 43]. Procedural guidelines for SIRT have been published [44].…”

Section: Selective Internal Radioembolization Of Malignant Liver Lesionsmentioning

confidence: 99%

Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment

Jadvar

2017

American Journal of Roentgenology

View full text Add to dashboard Cite

Objective This article reviews recent developments in targeted radionuclide therapy (TRT) approaches directed to malignant liver lesions, bone metastases, neuroendocrine tumors, and castrate-resistant metastatic prostate cancer and discusses challenges and opportunities in this field. Conclusion TRT has been employed since the first radioiodine thyroid treatment almost 75 years ago. Progress in the understanding of the complex underlying biology of cancer and advances in radiochemistry science, multimodal imaging techniques including the concept of “see and treat” within the framework of theranostics, and universal traction with the notion of precision medicine have all contributed to a resurgence of TRT.

show abstract

Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation

Cited by 61 publications

References 30 publications

Tumor-Specific D-Dimer Concentration Ranges and Influencing Factors: A Cross-Sectional Study

Tumor-Specific D-Dimer Concentration Ranges and Influencing Factors: A Cross-Sectional Study

⁹⁰Y Hepatic Radioembolization: An Update on Current Practice and Recent Developments

Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment

Contact Info

Product

Resources

About

Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation

Cited by 61 publications

References 30 publications

Tumor-Specific D-Dimer Concentration Ranges and Influencing Factors: A Cross-Sectional Study

Tumor-Specific D-Dimer Concentration Ranges and Influencing Factors: A Cross-Sectional Study

90Y Hepatic Radioembolization: An Update on Current Practice and Recent Developments

Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment

Contact Info

Product

Resources

About

⁹⁰Y Hepatic Radioembolization: An Update on Current Practice and Recent Developments